First-line and second-line systemic treatments of patients with metastatic cutaneous melanoma (without brain metastasis) : French national guidelines.

Date publication

février 2014

Auteurs

Membres identifiés du Cancéropôle Est :
Pr TRUC Gilles

Tous les auteurs :
Cupissol D, Sassolas B, Combemale P, Modiano P, Bedane C, Derrey S, Dygai-Cochet I, Lamant L, Lubrano V, Mirabel X, Mourregot A, Bugat MER, Siegrist S, Thariat J, Tiffet O, Truc G, Verdoni L, Mazeau-Woynar V, Planchamp F, Leccia MT

Résumé

the emergence of new molecules for the treatment of metastatic cutaneous melanoma with a significant benefit on the survival brings new therapeutic perspectives. Nevertheless, their respective use and place in the therapeutic strategy are still debated by healthcare professionals. Objective: the French National Cancer Institute leads a national clinical practice guidelines project since 2008. It realized a review of these modalities of treatment and established recommendations. the clinical practice guidelines development process is based on systematic literature review and critical appraisal by experts. The recommendations are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines are reviewed by independent practitioners in cancer care delivery. this article presents recommendations for first-line and second-line systemic treatment of metastatic cutaneous melanoma (without brain metastatis).

Référence

Oncologie. 2014 Feb;16(2-3):137-47.